ACVR1 (also BMPR1 or ALK2) was downregulated in PAH PAECs, which aligns with established dysfunctional BMP/TGF-β signaling in experimental PH21 and is a new therapeutic target in PAH22. The gene discussed is ACVR1; the disease is pulmonary arterial hypertension.